More than 20 years of successful work in molecular biology areas, mainly developing genetically engineered model systems. Combined 14 years working experience as Head of EMBL Rome Gene Expression Facility and the MRC WIMM Genome Engineering Facility at the University of Oxford. Currently head of the Evotec Göttingen Cell Therapy hiPSC engineering platform. My team is responsible for human induced pluripotent stem cell genome engineering to develop custom fit lines for our diverse portfolios of cell therapy applications. Our main disease and development areas cover cancer treatment (immuno-oncology), metabolic diseases and heart repair. Ultimately, we want to provide safe and highly effective cell therapy products to as many patients as possible. We are constantly seeking partners to fully leverage our platform and accelerate projects towards transformative therapies, both within existing and to expand into new disease areas. Partnership models are flexible, and the relative contribution of EVOTEC and the respective partner at each stage of the project is mutually agreed on a project-by-project phase. If our asset is of interest you can find more information at https://www.evotec.com/en/innovate/ipsc-platform.